0800 Immune

0800 466 863

NeisVac-C

Common name:

MenCCV, monovalent meningococcal conjugate vaccine

Protects against meningococcal disease caused by Neisseria meningitidis group C.

tabs

Overview

Meningococcal disease is caused by the bacterium Neisseria meningitidis. At least 12 groups have been identified, including groups A, B, C, X, Y and W (previously called W-135). The pattern of disease caused by each group varies by time and country or geographical areas.groups have been identified, including groups A, B, C, Y and W. In New Zealand from 2015 to 2017, groups B and C were the most frequent causes of meningococcal disease. However, this has changed since 2018 with an increase in disease caused by groups W or Y. Over 2018–2019, just under half of cases were caused by meningococcal group B, and just under half by groups C, W or Y. Meningococcal group A rarely causes disease in New Zealand.

In New Zealand, conjugate vaccines protect against groups A, C, Y and W (Menactra® or Nimenrix®) or group C only (NeisVac-C®), and the multicomponent recombinant vaccine protects against group B only (Bexsero®). For best protection against all meningococcal disease in New Zealand, separate vaccinations against group B disease and groups A, C, Y and W disease are recommended.

The MeNZB™ vaccine used in New Zealand between 2004 and 2011 was designed to target a specific type of meningococcal group B bacteria that caused a prolonged epidemic here in New Zealand.

NeisVac-C is a meningococcal conjugate vaccine to protect against meningococcal group C only. The vaccine is funded for children aged under 9 months with a medical condition that increases their risk of invasive meningococcal disease AND is listed on the Pharmaceutical Schedule. NeisVac-C is also available as a purchased vaccine through your family doctor.

Responses to vaccine

NeisVac-C (MenCCV)

Common responses

  • Mild pain, redness and swelling around injection site

In infants and children:

  • Mild fever
  • Decreased appetite
  • Irritability
  • Malaise / tiredness

In adults

  • Headache

Rare responses

  • Muscle aches and pains
  • ​Hives

As with any medicine, very rarely a severe allergic reaction (anaphylaxis) can occur following immunisation.

References

  • Borrow R and Findlow J. Prevention of meningococcal serogroup c disease by NeisVac-C. Expert Rev Vaccines 2009 8(3) 265-279 doi: 10.1586/14760584.8.3.265.
  • Institute of Environmental Science and Research Ltd. Meningococcal disease quarterly report Jan - Dec 2019. Porirua: Institute of Environmental Science and Research Ltd (ESR); 2020
  • Lopez L, Sherwood J. The epidemiology of meningococcal disease in New Zealand 2013. Wellington: Institute of Environmental Science and Research Ltd (ESR); 2014. Report No.: FW14023.
  • Medsafe. New Zealand data sheet: NeisVac-C [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2008 [updated 2018 December 12; cited 2020 June 26]. Available from: https://www.medsafe.govt.nz/profs/Datasheet/n/NeisVacCinj.pdf 
  • Ministry of Health. Immunisation handbook 2017 2nd Edition [Internet]. Wellington: Ministry of Health; 2017 [updated March 2018; cited 2018 August 24]. Available from: https://www.health.govt.nz/publication/immunisation-handbook-2017.

 

In Depth

Other brands:

Meningococcal C only conjugate vaccine:

  • None

Meningococcal A, C, W, Y conjugate vaccines:

  • Menactra®
  • Nimenrix®

Meningococcal group B only recombinant vaccine

  • Bexsero®

Vaccine type: subunit conjugate

Schedule and administration

NeisVac-C® is funded for children aged under 9 months with a medical condition that increases their risk of meningococcal disease AND is listed on the Pharmaceutical Schedule. The vaccine is available for purchase for children and adults with a medical condition that is not listed on the Pharmaceutical Schedule. 

When available, use of meningococcal vaccine against the groups A, C, Y and W (Menactra or Nimenrix) is preferred over the group C only (NeisVac-C) vaccine due to the observed increases in disease caused by groups W or Y since 2018.

    Special groups

    NeisVac-C is recommended and funded for children aged under months:

    • Two doses for a close contact of meningococcal C disease case, post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days.

    Catch-up doses

    Not relevant

    Storage and preparation

    Store as per cold chain between 2°C to 8°C.

    NeisVac-C is presented as a semi-opaque white to off-white suspension in single dose syringe. Upon storage a white deposit and clear supernatant can be observed. The vaccine should be shaken thoroughly before us. After shaking, the vaccine should be a homogeneous semi-opaque white to off-white suspension.

    Administration

    NeisVac-C can be administered at the same visit as other vaccines including all vaccines on the National Immunisation Schedule.

    NeisVac-C is for intramuscular use only, preferably in the vastus lateralis in infants and the deltoid region in older children, adolescent and adults. The vaccine must not be administered subcutaneously or intravenously.

    For:

    Infants and children aged 8 weeks to 11 months:**

    • Two doses 8 weeks apart
    • Booster at 12 months of age or a minimum of 6 months after second dose, at least 8 weeks after 2nd dose

    Children aged 12 months to under 7 years:**

    • One dose
    • If still at risk 2–3 years later – offer a booster dose

    Children aged 7 years or over and adults:**

    • One dose
    • If still at risk 5 years later – offer a booster dose

    **When available, use of meningococcal vaccine against the groups A, C, Y and W (Menactra or Nimenrix) is preferred over the group C only (NeisVac-C) vaccine due to the observed increases in disease caused by groups W or Y since 2018.

    Vaccine safety

    More than 20 years of studies and safety monitoring have shown that the conjugate meningococcal vaccines have excellent safely profiles.

    NeisVac-C should not be given to:

    • Anyone with severe allergy (anaphylaxis) to a previous dose of a meningococcal vaccine or a component of the vaccine
    • Administration of NeisVac-C should be postponed in individuals suffering from a fever over 38°C. The presence of a minor infection is not a reason to delay immunisation

    Specialist advice should be sought for the following groups:

    • Those with bleeding disorders, such as haemophilia. The vaccine should be administered in accordance with the haematologist’s instructions

    Vaccine effectiveness

    Protection against meningococcal disease is dependent on an individual having adequate existing circulating protection provided by antibodies because the bacteria cause disease more quickly than the immune system can generate new protection. Immunisation generates circulating antibodies. Over time the antibody levels decrease. The number and quality of antibodies and how long they last depend on what type of vaccine is used, the meningococcal group(s) covered by the vaccine, and the age of the person receiving the vaccine.

    As there are generally low numbers of meningococcal disease cases in countries such as Australia, England, Germany, New Zealand and the United States it is not possible to determine exactly how many cases of disease are prevented by vaccination and how long protection after vaccination lasts. Instead, the immune system response and antibody levels are used as an alternative measure of how well and how long meningococcal vaccines can protect from disease.

    After completion of the recommended vaccination course:

    • Infants and young children aged 2–13 months: 97–100% had protective levels of circulating antibodies.
    • Children aged 12–17 months: 97–100% had protective levels of circulating antibodies.
    • Children aged 3–6 years: 100% had protective levels of circulating antibodies.
    • Adolescents aged 13–17 years: 100% had protective levels of circulating antibodies.
    • Adults aged 18 years or older: 100% had protective levels of circulating antibodies.

     

    Last updated: Jul 2020